Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Gilbert YoussefRifaquat RahmanCamden BayWei WangMary Jane Lim-FatOmar ArnaoutWenya Linda BiDaniel N CagneyYuh-Shin ChangTimothy F CloughesyMatthew N DeSalvoBenjamin M EllingsonThomas F FloodElizabeth R GerstnerL Nicolas Gonzalez CastroJeffrey P GuenetteAlbert E KimEudocia Quant LeeJose R McFaline-FigueroaChristopher A PotterDavid A ReardonRaymond Y HuangPatrick Yung WenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
RANO and mRANO demonstrated similar correlations between PFS and OS. Confirmation scans were only beneficial in nGBM within 12 weeks of completion of radiotherapy, and there was a trend in favor of the use of postradiation MRI as the baseline scan in nGBM. Evaluation of FLAIR can be omitted. The iRANO criteria did not add significant benefit in patients who received immune checkpoint inhibitors.